Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Distenda
- Development stage
- Preclinical
- Lead developer
- Cannabis Bioscience International
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Distenda is a cannabinoid-based therapeutic candidate developed by Cannabis Bioscience International for the treatment of sleep-related conditions, including sleep apnea and insomnia. Formulated as an oral disintegrating strip (ODS), the drug is designed to provide a rapid-onset delivery method for its cannabinoid active ingredients via the oral mucosa, potentially improving bioavailability and patient compliance compared to traditional oral forms. It is currently in preclinical development, targeting the modulation of sleep patterns and respiratory control through the endocannabinoid system.
- Brand names
- Distenda
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on Distenda.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Distenda.